J&J Loses Jury Trial on Warnings of Levaquin Risk

Johnson & Johnson failed to properly warn of the risks of tendon damage linked to its antibiotic Levaquin, a Minnesota jury said in the first trial on claims over the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.